![Klaus Sindahl](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Klaus Sindahl
Investor Relations Contact chez
EMBLA MEDICAL HF.
Profil
Mr. Klaus Sindahl is a Head-Investor Relations at Embla Medical hf and a Head-Investor Relations at Hansa Biopharma AB. Mr. Sindahl was previously employed as an Investor Relations Officer by Novozymes A/S.
Postes actifs de Klaus Sindahl
| Sociétés | Poste | Début |
|---|---|---|
| EMBLA MEDICAL HF. | Investor Relations Contact | 01/05/2024 |
Anciens postes connus de Klaus Sindahl
| Sociétés | Poste | Fin |
|---|---|---|
| HANSA BIOPHARMA AB | Investor Relations Contact | 01/05/2024 |
Novozymes A/S
 Novozymes A/S Chemicals: SpecialtyProcess Industries Manufactures and sells specialty chemicals | Public Communications Contact | 01/01/2018 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
73
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Manufactures and sells specialty chemicals | Process Industries |
Embla Medical hf
 Embla Medical hf Medical SpecialtiesHealth Technology Provides non-invasive orthopedic products and support services | Health Technology |
Hansa Biopharma AB
 Hansa Biopharma AB Pharmaceuticals: MajorHealth Technology Develops therapies and medicines for the treatment of immunomodulatory | Health Technology |
